Navigation Links
Eloxatin in Medical News

Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan

...eria . No patient in any dose group exhibited any signs of acute neurotoxicity, which is a major adverse side-effect of the approved DACH platinum, eloxatin , and ProLindac was well tolerated overall. The Company has scaled up manufacturing in order to begin the next phase of clinical development. Access ...

Sanofi-aventis Announces Good First-quarter 2009 Performance

...cation approved in the second half of 2008. In the United States, the product posted 2.9% growth in net sales to euro 197 million. Net sales of eloxatin (R) , the leading cytotoxic agent in the colorectal cancer market as an adjuvant and as first line treatment in the metastatic phase, were up 3.0% at...

Sanofi-aventis Delivers 2008 Results Above Guidance

...sed by 17.8% (to EUR 49 million) in the fourth quarter and by 14.9% (to EUR 142 million) over the full year. In the United States, net sales of eloxatin (R) , the leading cytotoxic agent in the colorectal cancer market as an adjuvant and in the metastatic phase, rose by 6.9% to EUR 265 million in the ...

Eloxatin combination reduces bowel cancer recurrences

...study involving patients taking supplementation of eloxatin drug with other chemotherapeutic cancer drug for t...s called as NICE study has proved a combination of eloxatin with chemotherapeutic drugs more effective than co...nic acid. The study has found combination of eloxatin with 5-Fluorouracil and Folinic acid more effectiv...
Eloxatin in Medical Technology

New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data

... noted Dr. de Gramont. "Inclusion of these survival results in the new U.S. eloxatin PI marks an important milestone in the treatment of colon cancer." About ...two weeks for 12 cycles. The primary endpoint evaluated how the addition of eloxatin affected disease-free survival at three years. Secondary endpoints included...

Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review

...r Stage III colon cancer patients." In the MOSAIC trial, Stage III colon cancer patients treated after complete surgical resection of the tumor with eloxatin in combination with infusional 5-FU/LV had a significant reduction (20%) in the risk of dying after a median of six years compared to standard 5FU/LV-...

Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research

...atment of patients with advanced carcinoma of the colon or rectum. In 2004, eloxatin received additional approval for the first-line treatment of these patients. Based on data showing improvement in disease-free survival, eloxatin was also approved in 2004 for use in combination with infusional 5-FU/LV in...

The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer

...s were resected; of these, 115 patients (63%) received post-operative chemotherapy. In the standard arm, 152 patients' liver metastases were resected. eloxatin is not approved for peri-operative use in the United States. About Colorectal Cancer Colorectal cancer is a leading cause of death. Every year, ab...
Eloxatin in Medical Dictionary

Injection

...se. Read more about the prescription drug OXALIPLATIN - INJECTION . ... home > oxaliplatin- injection index > oxaliplatin- injection , eloxatin drug monograph ... Consumer information about the medication FOLIC ACID - INJECTION (Folvite), includes side effects, drug interactions, rec...
Eloxatin in Biological Technology

The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.

...in New York (NYSE: SNY ). For more information, visit: www.sanofi-aventis.us or www.sanofi-aventis.com . Please see the accompanying eloxatin (oxaliplatin injection), Lovenox (enoxaparin sodium injection), and Taxotere (docetaxel) Injection Concentrate full prescribing information, including...

Sanofi-aventis Announces Second Quarter 2009 Results

...h metastatic breast cancer, based on the results of the AVADO study. First-half net sales of Taxotere((R)) were up 9.5% at euro 1,118 million. eloxatin ((R)) , the leading cytotoxic agent in the colorectal cancer market as an adjuvant and as a first-line treatment in the metastatic phase, achieved se...

Hospira Receives Favorable Court Decision on Eloxatin(R)

...e generic name oxaliplatin injection, will be one of the first generic versions available in the United States to come in solution form. U.S. sales of eloxatin last year were approximately $1.4 billion. "We are extremely pleased with the court's ruling," said Joshua Gordon, vice president, Specialty Phar...

Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

...). Results also continue to indicate that both regimens have similar anti-tumor activity in first-line metastatic CRC. Net sales in 2007 in the US for eloxatin (oxaliplatin) were approximately $1.3 billion. "These new data continue to suggest that picoplatin is an active platinum agent in colorectal canc...

Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL

...ug Application (ANDA) containing a paragraph IV certification for a generic eloxatin product with the U.S. Food & Drug Administration (FDA), and following FDA n...rmally initiates the patent challenge process under the Hatch-Waxman Act. eloxatin (Oxaliplatin Aqueous Solution), 5mg/mL Injectable, used in combination with...

Access Highlighted in Recent BusinessWeek Article

...rcial also noted that Dr. Esteban Cvitkovic, Access' Vice-Chairman (Europe) and Senior Director, Oncology Clinical R&D, was responsible for developing eloxatin during his tenure at Sanofi-Aventis. The article references certain products of Somanta Pharmaceuticals in the cancer area. While Access has executed ...
Other Tags
(Date:8/29/2015)... ... August 29, 2015 , ... People who have heart or ... or asthma, are at higher risk from wildfire smoke especially in Calgary, Alberta.Those ... heart-rhythm problems (arrhythmia or irregular heartbeat) are also sensitive to air pollution. ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences ... sell Arterosil and Arterosil HP, and that all claims and counterclaims have been ... Sciences, LLC (VHS) in the United States District Court for the Southern District ...
(Date:8/28/2015)... ... August 28, 2015 , ... An online provider of CPAP machines, masks, supplies, ... CPAP equipment more affordable by offering shipping at no cost to you, directly to ... orders of any size. My Cpap Store is located in Las Vegas, Nevada. , ...
(Date:8/28/2015)... ... 28, 2015 , ... An article published August 19th by the ... gone through to open a pizzeria in Westchester. Mr. LaRocco was aware from opening ... months, but the current process, having already gone on for over a year, is ...
(Date:8/28/2015)... Falls Church, VA (PRWEB) , ... ... ... and Cybersecurity Risk Management for Medical Devices:, Understanding the FDA’s Position and ... – Rockville, MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally ...
Breaking Medicine News(10 mins):Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/5/2015)... According to a new market ... Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, ... to 2020", published by MarketsandMarkets, defines and segments the ... segments. The global PIAM Market is estimated to grow ... 2019, at a CAGR of 14.9 % from 2014 ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
Other Contents